CDK5 and chronic kidney disease: That profibrotic cellular dedifferentiation in CKD can be targeted therapeutically by inhibition of CDK5 not only validates the kinase as a therapeutic target in fibrosis, but also suggests that other downstream pathways could represent additional antifibrotic targets as well.